Cannabinoid hyperemesis syndrome

Lore & Background

CHS has three phases: prodromal, hyperemetic, and recovery. The prodromal phase involves mild symptoms such as nausea, anxiety, and increased thirst, which can last months to years. The hyperemetic phase features persistent nausea, vomiting, abdominal pain, and retching up to five times per hour, with acute episodes lasting 24–48 hours. During this phase, patients often present to emergency departments and may learn that long hot showers or baths relieve symptoms, leading to compulsive hot water bathing. The recovery phase begins after cannabis abstinence, with symptom resolution typically within two weeks but sometimes taking one to three months.

Reader's Guide

Cannabinoid hyperemesis syndrome is significant because it represents a harmful consequence of chronic cannabis use, contrasting with the drug's antiemetic reputation. Diagnosis relies on symptoms, a history of frequent cannabis use, and ruling out other causes. The only curative treatment is complete abstinence, with symptoms usually remitting within two weeks, though some patients experience symptoms for up to 90 days. Supportive care during episodes includes hydration and tentative evidence for capsaicin cream. Hot water hydrotherapy serves as both a diagnostic indicator and short-term palliative treatment. Distinguishing CHS from cyclic vomiting syndrome is crucial, as cessation of cannabis resolves CHS but not CVS. Complications can include kidney failure and electrolyte imbalances, with the first known deaths reported in a 2016 case study. The syndrome's pathogenesis remains unclear, with theories involving cannabinoid buildup, receptor function, and genetic predisposition.

Did You Know?

• Frequent hot showers or baths are both a diagnostic indicator and a short-term palliative treatment for CHS.
• The first known deaths associated with CHS were documented in a 2016 case series, involving two men who died from complications of severe vomiting and dehydration: one from acute renal failure and one from hypovolemic sh
• CHS symptoms are paradoxical because cannabinoids are well known for their antiemetic properties.
• The prodromal phase can last for months to years, and some individuals may attempt to treat their symptoms with cannabis use.

The Paradox and the Three Phases

Cannabinoids are widely recognized for their ability to suppress nausea, which makes the emergence of Cannabinoid Hyperemesis Syndrome a genuine clinical paradox. Rather than alleviating gastrointestinal distress, chronic cannabis use in susceptible individuals triggers a cyclical pattern of severe nausea, vomiting, and cramping abdominal pain. The syndrome unfolds across three distinct stages. The prodromal phase is the most insidious, lasting months or even years, during which patients experience only mild nausea, anxiety about vomiting, slight abdominal discomfort, sweating, and heightened thirst. Compulsive hot bathing is rarely a feature at this stage, and some individuals may actually increase their cannabis use in an attempt to self-treat. The hyperemetic phase marks the full-blown crisis: persistent vomiting and retching can occur as frequently as five times per hour, with acute episodes lasting one to two days. These bouts recur unpredictably over weeks or months. Oral intake of food and medication becomes nearly impossible, breeding a fear of eating, progressive weight loss, and dehydration that often drives patients to the emergency department. The recovery phase follows sustained abstinence, though the timeline for full resolution remains variable.

Diagnosis and the Telling Hot Water Sign

Because no single laboratory test or imaging study confirms the condition, clinicians must rely on a careful symptom history and the systematic exclusion of other causes of persistent vomiting. The syndrome was first formally described in the medical literature in 2004, and simplified diagnostic criteria did not appear until 2009, meaning many patients endured years of unexplained illness before receiving a label. A key diagnostic clue is the patient's pattern of cannabis use—typically weekly or more frequent consumption over several months, sometimes involving high-potency products or synthetic cannabinoids. Equally telling is the compulsion to take prolonged hot showers or baths, a behavior patients often discover through trial and error. They describe the relief as temperature-dependent, with hotter water providing greater comfort; in the medical literature this practice is termed hot water hydrotherapy. Distinguishing CHS from the similarly presenting cyclic vomiting syndrome can be challenging, particularly because many people with CVS use cannabis to ease their own symptoms. The critical differentiator is that stopping cannabis resolves CHS but leaves CVS untouched, and CVS characteristically peaks in the early morning, a pattern not typical of CHS.

Treatment, Recovery, and the Relapse Trap

The single proven cure for CHS is complete cessation of cannabis use, a fact that makes the condition both straightforward in principle and deeply difficult in practice. In many patients, symptoms begin to fade within two weeks of abstinence, yet a subset continues to experience nausea, cyclic vomiting, or abdominal discomfort for as long as ninety days. During acute hyperemetic episodes, medical care is largely supportive—oral or intravenous hydration being the cornerstone—while tentative evidence supports the application of capsaicin cream to the abdomen as a short-term adjunct. The greatest clinical challenge, however, is preventing relapse. Patients who resume cannabis often find their symptoms return, and a vicious cycle takes hold: tolerance develops, they shift to higher-potency products to achieve the desired effect, and when nausea reappears they consume even more cannabis because of its initial antiemetic properties. Breaking this loop requires targeted education about the cycle itself, combined with evidence-based interventions for cannabis use disorder such as motivational interviewing and structured relapse-prevention programs.

Unresolved Mechanisms and Life-Threatening Complications

Despite more than two decades of research since the syndrome's first description, the precise pathophysiology of CHS remains elusive. Cannabis contains over four hundred distinct chemicals, roughly sixty of which are cannabinoids, and the specific compound or combination responsible for triggering the syndrome has not been identified. Several mechanistic theories have been proposed, including a dose-dependent accumulation of cannabinoids producing a toxic effect, dysregulation of cannabinoid receptors in the hypothalamus (the brain region governing body temperature and digestive function), and direct stimulation of cannabinoid receptors within the gastrointestinal tract. Genetic predisposition to atypical cannabinoid metabolism, chronic psychological stress, and emotional factors may all modulate an individual's susceptibility, but none has been definitively established. The clinical stakes are high: prolonged vomiting and dehydration can progress to electrolyte disturbances and acute kidney injury. In 2016, a case report documented the first known fatalities directly attributed to CHS, in which two men succumbed to hyponatremic dehydration—a sobering reminder that what is often dismissed as a manageable gastrointestinal complaint can, in severe and untreated cases, prove fatal.